A Summary of Report of the Council for International Organizations of Medical Sciences (CIOMS) Working Group X on Evidence Synthesis and Meta-Analysis for Drug Safety

doi:10.19803/j.1672-8629.2020.02.12

Abstract

Abstract: Meta-analysis is the most important quantitative method in evidence-based medicine and has been widely applied to assess the efficacy during (and after) drug development. Recently, Meta-analysis used in studying safety outcomes has had a major impact on clinical or drug regulatory decisions. However, due to the difference of study design between safety and efficacy study, there are currently a number of challenges to the use of Meta-analysis to study drug safety. Hence, this paper is intended to present the aims of the CIOMS X guidance document, including comments on the intended audiences for the document. We present the key issues in Meta-analysis for drug safety, focusing on Meta-analyses of randomized clinical trials.

Key words: Meta-analysis, drug safety

CLC Number:

R994.11

Jesse A. BERLIN, FANG Xiaoyan, ZHANG Yongjing. A Summary of Report of the Council for International Organizations of Medical Sciences (CIOMS) Working Group X on Evidence Synthesis and Meta-Analysis for Drug Safety[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 121-125.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2020.02.12

https://zgywjj.magtechjournal.com/EN/Y2020/V17/I2/121

References

[1] CIOMS Working Group X. Evidence Synthesis and Meta-Analysis for Drug Safety: Report of CIOMS Working Group X[S/OL]. (2016)[2019-07-01]. https://cioms.ch/shop/product/evidence-synthesis-and-Meta-analysis-report-of-cioms-working-group-x/.
[2] Nissen SE, Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med, 2007, 356(24): 2457-2471.
[3] Tucker ME. FDA Lifts Final Regulatory Restrictions on Rosiglitazone [EB/OL]. (2015-12-16) [2019-07-01]. http://www.medscape.com/viewarticle/856056.
[4] Yahav D, Paul M, Fraser A, et al.Efficacy and safety of cefepime: a systematic review and Meta-analysis[J]. Lancet Infect Dis, 2007, 7(5): 338-348.
[5] Kim PW, Wu Y-T, Cooper C, et al.Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use[J]. Clinical Infectious Diseases, 2010, 51(4): 381-389.
[6] U.S. Food and Drug Administration. Guidance for industry: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes[EB/OL]. (2018-09-19) [2019-07-01]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf.
[7] U.S. Food and Drug Administration. Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products[EB/OL]. (2018-11-15) [2019-07-01]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/Meta-analyses-randomized-controlled-clinical-trials-evaluate-safety-human-drugs-or-biological.
[8] The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 6)[EB/OL].(2017-07) [2019-07-01]. http://www.encepp.eu/standards_and_guidances/meth-odologicalGuide.shtml.
[9] Crowe BJ, Xia HA, Berlin JA, et al.Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team[J]. Clin Trials, 2009, 6(5): 430-440.
[10] PROSPERO. About PROSPERO[EB/OL]. [2019-07-01] http://www.crd.york.ac.uk/prospero/#aboutpage.
[11] O'neill R. Assessment of safety, in Biopharmaceutical Statistics for Drug Development[M]. Marcel Dekker, 1988:543-604.
[12] Gleser L, Olkin I.The handbook of research synthesis and Metaan-alysis[M]. New York: Russell Sage Foundation, 1994:357-376.

[1]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[2]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[3]	LIU Yiyu, LI Yanwen, WANG Jiao, ZHOU Wenjing, PENG Yumeng, HE Wenbin, LI Zhiyong. Efficacy Semantic Mining and Safety Analysis of Chinese Patent Medicines for Headache [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 674-679.
[4]	FAN Liping, LU Shu, SUN Huiyuan. Efficacy and Safety of Panax Quinquefolium Saponin in Adjuvant Treatment of Angina Pectoris of Coronary Heart Disease: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 570-574.
[5]	WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping. Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
[6]	FAN Liping, LU Shu, CAI Yueping, WAN Yuxiang, SUN Huiyuan. Kanglaite Combined with Gefitinib for Mid-Late Stage Lung Cancer：a Meta-Analysis and Trial Sequential Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 316-323.
[7]	LI Bo, XU Liu, XIE Yuqing, WANG Yiying, DONG Shuai, LIAN Jie, LI Guodong, CAO Huijuan. Safety and Efficacy of Chinese Herbal Patent Medicines for COVID-19: an Umbrella Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 155-161.
[8]	WANG Ping, CAO Huijuan, LI Mengqi, ZHANG Guozhi, LIU Jianping, JIN Xuejing. Toxicity of “Aconitum Carmichaelii-Pinellia Ternata” Incompatible Combination: a Systematic Review and Meta-Analysis of Experimental Studies on Rats [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 177-182.
[9]	LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming. Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
[10]	ZHANG Jing, ZHANG Kai, YI Zhanmiao. Efficacy and safety of salvianolic acid preparations for adjuvant therapy on related diseases of coronary heart disease, angina and cerebral infarction: a systematic review [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 910-915.
[11]	LIU Qian, LI Bo, SHU Xinyang. Lanqin oral liquid combined with antibacterial drugs for the treatment of acute tonsillitis: a systematic review and Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 916-920.
[12]	SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang. Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
[13]	WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng. Evaluation of drug safety with multicenter real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
[14]	CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng. Management of compound glycyrrhiza oral solution and recommendations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
[15]	SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui. Adverse events of abemaciclib in breast cancer patients based on US FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.